Literature DB >> 21978994

Submicromolar Aβ42 reduces hippocampal glutamate receptors and presynaptic markers in an aggregation-dependent manner.

Meagan L Wisniewski1, Jeannie Hwang, Ben A Bahr.   

Abstract

Synaptic pathology in Alzheimer's disease brains is thought to involve soluble Aβ42 peptide. Here, sterile incubation in PBS caused small Aβ42 oligomer formation as well as heterogeneous, 6E10-immunopositive aggregates of 80-100kDa. The high molecular weight aggregates (H-agg) formed in a time-dependent manner over an extended 30-day period. Interestingly, an inverse relationship between dimeric and H-agg formation was more evident when incubations were performed at 37°C as compared to 23°C, thus providing an experimental strategy with which to address synaptic compromise produced by the different Aβ aggregates. H-agg species formed faster and to higher levels at 37°C compared to 23°C, and the two aggregate preparations were evaluated in hippocampal slice cultures, a sensitive system for monitoring synaptic integrity. Applied daily at 80-600nM for 7days, the Aβ42 preparations caused dose-dependent and aggregation-dependent declines in α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) and N-methyl-d-aspartate (NMDA) receptor subunits as well as in presynaptic components. Unlike the synaptic effects, Aβ42 induced only trace cellular degeneration that was CA1 specific. The 37°C preparation was less effective at decreasing synaptic markers, corresponding with its reduced levels of Aβ42 monomers and dimers. Aβ42 dimers decayed significantly faster at 37°C than 23°C, and more rapidly than monomers at either temperature. These findings indicate that Aβ42 can self-aggregate into potent synaptotoxic oligomers as well as into larger aggregates that may serve to neutralize the toxic formations. These results will add to the growing debate concerning whether high molecular weight Aβ complexes that form amyloid plaques are protective through the sequestration of oligomeric species. Copyright Â
© 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21978994      PMCID: PMC3226336          DOI: 10.1016/j.bbadis.2011.09.011

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  66 in total

1.  Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.

Authors:  C A McLean; R A Cherny; F W Fraser; S J Fuller; M J Smith; K Beyreuther; A I Bush; C L Masters
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

2.  Intraneuronal Abeta42 accumulation in human brain.

Authors:  G K Gouras; J Tsai; J Naslund; B Vincent; M Edgar; F Checler; J P Greenfield; V Haroutunian; J D Buxbaum; H Xu; P Greengard; N R Relkin
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

3.  Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.

Authors:  Dominic M Walsh; Igor Klyubin; Julia V Fadeeva; William K Cullen; Roger Anwyl; Michael S Wolfe; Michael J Rowan; Dennis J Selkoe
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

4.  Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease.

Authors:  C I Sze; J C Troncoso; C Kawas; P Mouton; D L Price; L J Martin
Journal:  J Neuropathol Exp Neurol       Date:  1997-08       Impact factor: 3.685

5.  Survival signaling and selective neuroprotection through glutamatergic transmission.

Authors:  Ben A Bahr; Jennifer Bendiske; Queenie B Brown; Subramani Munirathinam; Ebru Caba; Markus Rudin; Stephan Urwyler; André Sauter; Gary Rogers
Journal:  Exp Neurol       Date:  2002-03       Impact factor: 5.330

6.  The evolution of A beta peptide burden in the APP23 transgenic mice: implications for A beta deposition in Alzheimer disease.

Authors:  Y M Kuo; T G Beach; L I Sue; S Scott; K J Layne; T A Kokjohn; W M Kalback; D C Luehrs; T A Vishnivetskaya; D Abramowski; C Sturchler-Pierrat; M Staufenbiel; R O Weller; A E Roher
Journal:  Mol Med       Date:  2001-09       Impact factor: 6.354

Review 7.  Structural correlates of cognition in dementia: quantification and assessment of synapse change.

Authors:  S T DeKosky; S W Scheff; S D Styren
Journal:  Neurodegeneration       Date:  1996-12

8.  Intracellular deposition, microtubule destabilization, and transport failure: an "early" pathogenic cascade leading to synaptic decline.

Authors:  Jennifer Bendiske; Ebru Caba; Queenie B Brown; Ben A Bahr
Journal:  J Neuropathol Exp Neurol       Date:  2002-07       Impact factor: 3.685

Review 9.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

10.  Lysosomal membrane damage in soluble Abeta-mediated cell death in Alzheimer's disease.

Authors:  K Ditaranto; T L Tekirian; A J Yang
Journal:  Neurobiol Dis       Date:  2001-02       Impact factor: 5.996

View more
  9 in total

1.  Positive lysosomal modulation as a unique strategy to treat age-related protein accumulation diseases.

Authors:  Ben A Bahr; Meagan L Wisniewski; David Butler
Journal:  Rejuvenation Res       Date:  2012-04       Impact factor: 4.663

2.  Paraoxon: An Anticholinesterase That Triggers an Excitotoxic Cascade of Oxidative Stress, Adhesion Responses, and Synaptic Compromise.

Authors:  Karen L G Farizatto; Ben A Bahr
Journal:  Eur Sci J       Date:  2017-10

3.  Blast waves from detonated military explosive reduce GluR1 and synaptophysin levels in hippocampal slice cultures.

Authors:  Marquitta Smith; Thuvan Piehler; Richard Benjamin; Karen L Farizatto; Morgan C Pait; Michael F Almeida; Vladimir V Ghukasyan; Ben A Bahr
Journal:  Exp Neurol       Date:  2016-10-05       Impact factor: 5.330

4.  Aβ42-mediated proteasome inhibition and associated tau pathology in hippocampus are governed by a lysosomal response involving cathepsin B: Evidence for protective crosstalk between protein clearance pathways.

Authors:  Karen L G Farizatto; Uzoma S Ikonne; Michael F Almeida; Merari F R Ferrari; Ben A Bahr
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

5.  Early Synaptic Alterations and Selective Adhesion Signaling in Hippocampal Dendritic Zones Following Organophosphate Exposure.

Authors:  Karen L G Farizatto; Michael F Almeida; Ronald T Long; Ben A Bahr
Journal:  Sci Rep       Date:  2019-04-25       Impact factor: 4.379

Review 6.  Cellular Prion Protein as a Receptor of Toxic Amyloid-β42 Oligomers Is Important for Alzheimer's Disease.

Authors:  Yuan Zhang; Yanfang Zhao; Lei Zhang; Wanpeng Yu; Yu Wang; Wenguang Chang
Journal:  Front Cell Neurosci       Date:  2019-07-30       Impact factor: 5.505

7.  Distinct and dementia-related synaptopathy in the hippocampus after military blast exposures.

Authors:  Michael F Almeida; Thuvan Piehler; Kelly E Carstens; Meilan Zhao; Mahsa Samadi; Serena M Dudek; Christopher J Norton; Catherine M Parisian; Karen L G Farizatto; Ben A Bahr
Journal:  Brain Pathol       Date:  2021-02-24       Impact factor: 7.611

8.  The Role of Lysosomes in a Broad Disease-Modifying Approach Evaluated across Transgenic Mouse Models of Alzheimer's Disease and Parkinson's Disease and Models of Mild Cognitive Impairment.

Authors:  Jeannie Hwang; Candice M Estick; Uzoma S Ikonne; David Butler; Morgan C Pait; Lyndsie H Elliott; Sarah Ruiz; Kaitlan Smith; Katherine M Rentschler; Cary Mundell; Michael F Almeida; Nicole Stumbling Bear; James P Locklear; Yara Abumohsen; Cecily M Ivey; Karen L G Farizatto; Ben A Bahr
Journal:  Int J Mol Sci       Date:  2019-09-09       Impact factor: 5.923

9.  Acetylation of AMPA Receptors Regulates Receptor Trafficking and Rescues Memory Deficits in Alzheimer's Disease.

Authors:  Margaret O'Connor; Yang-Ping Shentu; Guan Wang; Wen-Ting Hu; Zhen-Dong Xu; Xiao-Chuan Wang; Rong Liu; Heng-Ye Man
Journal:  iScience       Date:  2020-08-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.